Publications by authors named "James D Griffin"

Claim this Profile
A
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain.
Marina C Primi, Maurício T Tavares, John M Hatcher, Hyelim Kang, Tomás A C Kresina, James D Griffin

Eur J Med Chem· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.
Antonino Glaviano, Ellen Weisberg, Hiu Y Lam, Donavan J J Tan, Andrew J Innes, James D Griffin

Nat Rev Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy.
Wei Ni, Swati Garg, Basudev Chowdhury, Martin Sattler, Dana Sanchez, James D Griffin

Mol Ther Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation-inducing chimera rewires oncogenic kinase to trigger apoptosis.
Manuel L Merz, Veronika M Shoba, Rajaiah Pergu, Zachary C Severance, Dhanushka N P Munkanatta Godage, James D Griffin

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs.
Wei Ni, Swati Garg, Basudev Chowdhury, Martin Sattler, Dana Sanchez, James D Griffin

Mol Ther Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD9 regulates normal human hematopoietic stem cell function and lineage differentiation.
Swati Garg, Wei Ni, Basudev Chowdhury, Ellen L Weisberg, Martin Sattler, James D Griffin

Cell Death Differ· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
Douglas W McMillin, Jake Delmore, Ellen Weisberg, Joseph M Negri, Corey D Geer, James D Griffin

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.
Basudev Chowdhury, Swati Garg, Wei Ni, Martin Sattler, Dana Sanchez, James D Griffin

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Physician Preferences for Acute Myeloid Leukemia Maintenance Treatments Following Hematopoietic Stem Cell Transplantation.
Lalit Saini, James D Griffin, Bhavik J Pandya, Manasee V Shah, Mo Zhou

Patient Prefer Adherence· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations.
Swati Garg, Wei Ni, James D Griffin, Martin Sattler

Hematol Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
Yiying Xue, Husheng Mei, Yisa Chen, James D Griffin, Qingsong Liu

MedComm (2020)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
RuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, J J Patten, Charles Zou, James D Griffin

J Med Virol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma.
Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, Abigail E Case, Wei Ni, James D Griffin

Blood Cancer J· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
Jing Yang, Ellen L Weisberg, Shuang Qi, Wei Ni, Husheng Mei, James D Griffin

Leukemia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Jing Yang, Ellen L Weisberg, Xiaoxi Liu, Robert S Magin, Wai Cheung Chan, James D Griffin

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.
James D Griffin, Yan Song, Hongbo Yang, Jonathan Freimark, Manasee V Shah

Eur J Haematol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
Kinan Alhallak, Pilar de la Puente, Amanda Jeske, Jennifer Sun, Barbara Muz, James D Griffin

Leuk Lymphoma· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Moshe Lapidot, Abigail E Case, Ellen L Weisberg, Chengcheng Meng, Sarah R Walker, James D Griffin

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma.
Zirong Chen, Wei Ni, Jian-Liang Li, Shuibin Lin, Xin Zhou, James D Griffin

JCI Insight· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM).
Moshe Lapidot, Abigail E Case, Dalia Larios, Helen I Gandler, Chengcheng Meng, James D Griffin

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Ellen Weisberg, Chengcheng Meng, Abigail Case, Martin Sattler, Hong L Tiv, James D Griffin

Leukemia· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current therapies under investigation for COVID-19: potential COVID-19 treatments.
Ellen Weisberg, Martin Sattler, Priscilla L Yang, Alexander Parent, Nathanael Gray, James D Griffin

Can J Physiol Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repurposing of Kinase Inhibitors for Treatment of COVID-19.
Ellen Weisberg, Alexander Parent, Priscilla L Yang, Martin Sattler, Qingsong Liu, James D Griffin

Pharm Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Jing Yang, Chengcheng Meng, Ellen Weisberg, Abigail Case, Ilaria Lamberto, James D Griffin

Br J Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Nathan J Schauer, Xiaoxi Liu, Robert S Magin, Laura M Doherty, Wai Cheung Chan, James D Griffin

Sci Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis